Climb Bio and Mabworks presented Phase 1 data for CLYM116/MIL116, an anti-APRIL antibody for IgA nephropathy, showing over 90% APRIL suppression and ~70% reduction in pathogenic Gd-IgA1 after 12 weeks from a single dose. The drug demonstrated a long half-life (~33 days) and was well tolerated with no serious side effects, supporting a convenient every-12-week dosing schedule. The ongoing NAVIGATE-2 Phase 2 trial is enrolling patients to confirm these findings, with initial results expected in early 2027 and a global Phase 3 trial planned for later that year. This progress offers hope for a new, effective treatment addressing the underlying cause of IgA nephropathy, a common autoimmune kidney disease.
Climb Bio and Mabworks' announcement on CLYM116/MIL116 data provides context for readers following health innovations. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 24, 2026 03:11 WIB: out of 150 priced US health-sector stocks, 62 rose and 88 fell. Notable movers include NUWE (Nuwellis Inc) at USD 0.39 with a 1-day change of -19.29% and Pluang order activity of 5% Sell / 95% Buy, typical hold time 29 days; TNGX (Tango Therapeutics Inc.) at USD 23.45, down 16.04%, with 87% Sell / 13% Buy, typical hold time 1 day; and WGS (GeneDx Holdings Corp) at USD 59.13, down 11.93%, with 48% Sell / 52% Buy, typical hold time 20 days.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
